US stocks ended lower on Friday as a negative mix of news -related news and inflation worried traders to exclude the week.
Friday's losses left the major averages in negative territory on the week. The industrial average of 30 Dow Jones stock surrendered 0.5%, the S&P fell by 500 0.2%and the NASDAQ compound fell technology-over 0.5%.
Source: Investment.com
The week to come is expected to be another exciting as investors measure the prospects for the economy, inflation and interest rates.
On the economic calendar, the most important will be the U.S. consumer price inflation report on Wednesday for January, which could fire further turmoil if it comes in higher than expectations. The CPI data will be accompanied by the latest figures on producer prices, which will help fill in the inflation picture, as well as the January Retail Sales report.
In the meantime, the view of the Fed rate could become clearer when Chairman Jerome Powell presents Semrieton's monetary monetary policy evidence to the House's Financial Services Committee on Tuesday and Wednesday.
Source: Investment.com
Traders now expect the US Central Bank to cut interest rates only once this year, abandoning earlier bets on two rate cuts starting in June, in line with the Fed Investing.com monitor tool.
Elsewhere, the busy earnings season continues with reports due from Cisco Systems (NASDAQ: CSCO), Shopify (NYSE: Shop), Coinbase (NASDAQ: Coin), Robinhood (NASDAQ: Hood), Applovin ( Applovin (Nasdaq: App), Reddit (Nyse (Nyse (Nyse (Nyse: RDDT), Palo Alto Networks (Nasdaq: Panw), McDonald's (Nyse: McD), Coca-Cola (NYSE: KO), Moderna (NASDAQ: MRNA ), Cvs health (nyse: cvs), airbnb: abnb: abnb: abnb: abnb: abnb), and doordash (nasdaq: dash).
No matter what direction the market is going, below I highlight one stock that is likely to be demand and another that could see a fresh disadvantage. Remember though, my schedule is righteous For the coming week, Monday, February 10 – Friday, February 14.
Robinhood, the un -commissioned trading app popular with retail investors, is expected to report its fourth -quarter earnings update after the closing on Wednesday at 4:05 pm ET, and expectations are high air.
Market participants anticipate a significant swing in hood stock after the print decreases, according to the options market, with a potential implicit movement of 12.4% in either direction. In a sign of growing confidence, the company has received three up -for -profit preview reviews in recent days, with no downward reforms.
Source: InvestingPro
Analysts anticipate earnings per share (EPS) of $ 0.52, representing a stunning increase of profits of $ 0.03 in the year ago. Revenue is projected to be almost double year -on -year to $ 951.8 million as Robinhood continues to expand its consumer base and take advantage of new momentum in crypto and equity trading.
The company has set itself as a leader in the retail investment point, benefiting from increased interest in stock and crypto trading. Improved operational efficiency and cost cutting measures have also improved profitability.
Furthermore, the retail brokerage company has made great strides in diversifying its revenue streams, especially through its growing options trading products and subscription.
Source: Investment.com
Shares from Robinhood have been on tears, hitting a series of records of records ever in recent sessions. Hood closed at $ 55.86 on Friday, winning a valuation of $ 49.4 billion to the company. The stock up 50% so far is 2025, as optimism builds around its ability to benefit from a properly retail trading wave.
In addition, Robinhood shows striking financial health, with an investment health score of 3.2 out of 5.0 (“great”), which reflects a strong balance sheet, improving cash flow and efficient operations.
On the other hand, Moderna is facing significant headgear going to its CH4 earnings report, which is intended to be released later this week. The results are expected before an opening bell on Friday at 6:35 am ET and the expected movement is about 11% up or down.
The high-flight vaccine maker is struggling with the declining demand for his Covid-19 shots, and analysts expect a disappointing quarter ahead of us in the midst of concerns about the growth of dilution, research spending and heavy development, and lack of diversification. In the three months leading up to the earnings update, analysts have broken their EPS estimates 12 times, compared to zero upward reforms.
Source: InvestingPro
Moderna is expected to post a Q4 loss of -$ 2.70 per share, a sudden reversal of the $ 0.55 profit recorded a year ago. Revenue is expected to dive nearly 70% year -on -year to $ 951.1 million.
The biotechnology company now faces the challenges of revenue growth with limited near -term catalysts to compensate for demand as vaccine sales continue to decline.
Moderna-free non-Covid pipeline offers little near-term relief. Its experimental flu and RSV vaccines are falling behind in established players, leaving it too dependent on a shrinking market.
Source: Investment.com
MRNA stock ended a session on Friday at $ 32.60, not far from a recent minimum of 52 weeks of $ 31.94, which is the weakest level since April 2020. At its current valuation, Moderna has a market cap of $ 12.5 billion. Shares, which trade under their key moving averages, are down 21.6% to start the new year.
In addition, Moderna has a financial health score lower than the average of 2.1 out of 5.0, reflecting concerns about weak revenue performance and slowdown growth prospects.
Whether you are a new investor or an experienced trader, execute Invest Can unlock a world of investment opportunities in reducing risks in the challenging background of the market.
• AI propicks: Stock winners selected by AI with a proven history.
• Investing a fair value: Find out immediately whether stock is underpinned or overvalued.
• Advanced Stock Screenser: Look for the best stocks based on hundreds of selected filters, and criteria.
• Top ideas: See what stocks billionaire investors like Warren Buffett, Michael Burry, and George Soros buy.
Disclosure: At the time of writing, I'm long on the S&P 500, and the NASDAQ 100 via the SPDR® S&P 500 ETF (SPY), and ETF Invesco QQQ ETF (QQQ). I am also long on the QQQ ETF (QBIG) Top Investo, Investo S&P 500 ETF (RSP) equal weight, and Vaneck ETF vectors semi -conductors (SMH).
I regularly balance my portfolio of individual stocks and ETFs based on a continuing risk assessment of the macro -economic and financial environment.
The views covered in this article are the author's views only and should not be taken as an investment advice.
Follow Jesse Cohen on X/Twitter @Jessecoheninv For more analysis and insight into the stock market.
